GGV Capital, a private equity firm, led a $100m Series A funding round in BioMap, a Chinese AI-driven R&D platform that focuses on precision medicine. Additional investors include Baidu, Legend Holdings’ Legend Capital, Bluerun Ventures, as well as Xiang He Capital, a TMT focused venture capital firm co-founded by Baidu’s former executives Hesong Tang and Maggie Yang. “The fields related to AI and life sciences have the best potential in the 21st century, while AI-driven drug discovery is widely known as one of the most sought-after accelerators in life science,” Chenxiao Wu, GGV Capital Partner.